Business

As a fast-growing emitter of greenhouse gases, the aviation industry is under intense pressure to improve its fuel efficiency. Kurt Kleiner surveys its options.

Most drug companies have tried to avoid making enemies of AIDS activist groups. But Abbott Laboratories' patience has snapped, as Erika Check reports.

As a BP project to capture carbon dioxide from a power station bites the dust, supporters argue that a major opportunity for Britain has been lost. Andrea Chipman reports.

A rash of problems has knocked some of the shine off one of the world's top biotechnology companies, as Meredith Wadman reports.

Light-emitting diodes are seen by many as the light source of the future. But as Kurt Kleiner reports, their adaptation will take time.

Support for copycat versions of biotechnology drugs is growing quickly in the US Congress. Meredith Wadman reports.

A handful of pioneers are trying to bring algae-based biofuels back from a near-death experience. Amanda Leigh Haag reports.

Despite its critics, the Alternative Investment Market could still be attractive to America's small, innovative companies, reports Andrea Chipman.

Long dismissed as too expensive or impractical, mining the sea floor for metals is gaining a new foothold. Mark Schrope reports on two companies hoping to take the plunge.

As AstraZeneca shells out $15 billion for a mid-sized US biotech firm, Heidi Ledford reports on the startling cost of staying in the drugs business.